Venture Capital Deals and Investments
  • All Technology
  • AI
  • Autonomy
  • B2B Growth
  • Big Data
  • BioTech
  • ClimateTech
  • Consumer Tech
  • Crypto
  • Cybersecurity
  • DevOps
  • Digital Marketing
  • Ecommerce
  • EdTech
  • Enterprise
  • FinTech
  • GovTech
  • Hardware
  • HealthTech
  • HRTech
  • LegalTech
  • Nanotech
  • PropTech
  • Quantum
  • Robotics
  • SaaS
  • SpaceTech
AllNewsDealsSocialBlogsVideosPodcastsDigests

Venture Capital Pulse

EMAIL DIGESTS

Daily

Every morning

Weekly

Sunday recap

NewsDealsSocialBlogsVideosPodcasts
Peptilogics Raises $78M in Oversubscribed Series B2 to Advance PLG0206
Series BVenture Capital

Peptilogics Raises $78M in Oversubscribed Series B2 to Advance PLG0206

•October 16, 2025
•Oct 16, 2025
0

Participants

Peptilogics

Peptilogics

company

presight capital

presight capital

investor

Thiel Bio

Thiel Bio

investor

Founders Fund

Founders Fund

investor

AMR Action Fund

AMR Action Fund

investor

Narya

Narya

investor

Beyond Ventures

Beyond Ventures

investor

Deal Summary

Peptilogics completed an oversubscribed $78M Series B2 financing to support Phase 2/3 trials of zaloganan (PLG0206) for prosthetic joint infections. The round was led by Presight Capital, Thiel Bio and Founders Fund, with participation from AMR Action Fund, Narya Capital and Beyond Ventures.

0

Comments

Want to join the conversation?

Loading comments...